Effect of vitamin D3 supplementation towards vitamin D serum levels and Myasthenia Gravis Composite Score (MGCS)

Abstract

Myasthenia gravis (MG) is due to the functional impairment Treg cell that is as important as controlling the activation of T cells and inhibit the autoimmune response. Vitamin D3 is known to have an effect on increasing the quantity of Treg cells in the peripheral blood circulation and also functional so that it can suppress T cell activation. This study used a double-blind randomized controlled trial of 20 patients MG during the period from April to July 2017. The bivariate analysis using independent t-test and paired T-test. Multivariate analysis using linear regression. The mean change MGCS after vitamin D3 treatment group and placebo were not statistically significant (p = 0531). On the addition of vitamin D3 MGCS 1:19 ± 0.1 (p = 0798). There is a significant change (p = 0.041) in the mean levels of vitamin D after treatment between vitamin D3 and placebo groups. A significant increase (p = 0.005) vitamin D levels after administration of vitamin D3 in the amount of 17.88 ± 29.5 Ng/ml. Multivariate analysis showed that the initial MGCS and IMT values that most influence on the final MGCS value, and levels of vitamin D beginning the most influence on the final vitamin D levels. Vitamin D3 is 800 IU / day had no effect on the value of MGCS but the effect on changes in levels of vitamin D in the blood.